Citius Pharma (CTXR)
NASDAQ:CTXR
Want to see CTXR full AI Analyst Report?
Top Page
Citius Pharmaceuticals
(NASDAQ:CTXR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.69
▼(-20.12% Downside)
Action:Reiterated
Date:05/19/26
The score is held down primarily by heavy operating losses and significant ongoing cash burn, alongside weak technical trend signals. Offsetting factors include low balance-sheet leverage and positive corporate developments around LYMPHIR commercialization and expansion, but profitability and funding needs remain the key risks.
Positive Factors
Low balance-sheet leverage
Very low debt-to-equity gives the company financial flexibility to fund commercialization and clinical programs without near-term interest burden. This durable balance-sheet strength reduces insolvency risk and preserves optionality for strategic partnerships or non-dilutive financing as revenue scales.
Negative Factors
High operating cash burn
Sustained negative operating and free cash flow at this scale creates structural funding pressure, forcing reliance on external capital or cost cuts. Persistent cash burn limits the company's ability to self-fund commercial scale-up or multiple late-stage trials and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low balance-sheet leverage
Very low debt-to-equity gives the company financial flexibility to fund commercialization and clinical programs without near-term interest burden. This durable balance-sheet strength reduces insolvency risk and preserves optionality for strategic partnerships or non-dilutive financing as revenue scales.
Read all positive factors
Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.25M
Dividend YieldN/A
Average Volume (3M)958.51K
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue GrowthN/A
EPS Growth55.15%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.57
Shares Outstanding27,452,570
10 Day Avg. Volume1,007,895
30 Day Avg. Volume958,514
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$4.00Price Target Upside365.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.66
Revenue Forecast (FY)$78.29M
Citius Pharmaceuticals Business Overview & Revenue Model
Company Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem ce...
How the Company Makes Money
null...
Citius Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.10M | -214.25K | -209.61K | -194.32K | -179.68K | -164.87K |
| EBITDA | -55.93M | -38.20M | -38.64M | -31.77M | -32.88M | -22.88M |
| Net Income | -46.20M | -37.43M | -39.14M | -32.54M | -33.64M | -23.13M |
Balance Sheet | ||||||
| Total Assets | 132.54M | 130.94M | 116.65M | 103.61M | 114.00M | 142.43M |
| Cash, Cash Equivalents and Short-Term Investments | 4.59M | 4.25M | 3.25M | 26.48M | 41.71M | 70.07M |
| Total Debt | 808.16K | 1.81M | 262.87K | 481.25K | 678.23K | 855.47K |
| Total Liabilities | 63.46M | 53.41M | 42.55M | 12.18M | 10.57M | 9.65M |
| Stockholders Equity | 61.54M | 67.55M | 70.08M | 90.83M | 102.83M | 132.18M |
Cash Flow | ||||||
| Free Cash Flow | -31.60M | -26.55M | -28.20M | -29.06M | -28.36M | -64.26M |
| Operating Cash Flow | -31.60M | -26.55M | -28.20M | -29.06M | -28.36M | -24.25M |
| Investing Cash Flow | -10.75M | -5.75M | -5.00M | 0.00 | 0.00 | -40.01M |
| Financing Cash Flow | 46.91M | 33.30M | 9.97M | 13.83M | 0.00 | 120.47M |
Citius Pharmaceuticals Technical Analysis
Neutral
0.86
Price Trends
0.75
Negative
0.78
Negative
1.02
Negative
Market Momentum
-0.04
Negative
51.06
Neutral
62.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.75, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 51.06 is Neutral, neither overbought nor oversold. The STOCH value of 62.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTXR.
Citius Pharmaceuticals Risk Analysis
Citius Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.72M | 2.78 | -27.54% | ― | ― | -138.25% | |
46 Neutral | $19.25M | -0.24 | -67.42% | ― | ― | 55.15% | |
44 Neutral | $23.34M | -1.97 | >-0.01% | ― | -43.86% | 49.21% | |
42 Neutral | $16.76M | -0.83 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
CTXR
Citius Pharmaceuticals
0.70
>-0.01
-0.28%
SYBX
Synlogic
0.66
-0.47
-41.59%
MRKR
Marker Therapeutics
1.40
0.26
22.81%
HOTH
Hoth Therapeutics
0.69
-0.17
-19.77%
PASG
Passage Bio
5.23
-1.94
-27.03%
Citius Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Positive
May 8, 2026
On May 4, 2026, Citius Pharmaceuticals and its majority-owned unit Citius Oncology amended a 2024 promissory note originally issued by Citius Oncology to the parent in the principal amount of about $3.8 million, aligning its payment and maturity t...
Business Operations and StrategyProduct-Related Announcements
Citius Expands LYMPHIR Access with First European Shipment
Positive
Apr 29, 2026
On April 29, 2026, Citius Oncology reported its first international shipment of LYMPHIR to Europe through a regional distribution partner, expanding access to the CTCL therapy beyond the U.S. via Named Patient Programs in select markets where the ...
Business Operations and StrategyPrivate Placements and Financing
Citius Pharmaceuticals Raises $5 Million in Securities Offering
Neutral
Apr 24, 2026
On April 23, 2026, Citius Pharmaceuticals entered into a securities purchase agreement with institutional investors for a $5 million capital raise via a registered direct offering and concurrent private placement. The company issued 4,730,457 comm...
Executive/Board ChangesShareholder Meetings
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
Neutral
Apr 6, 2026
On April 6, 2026, Citius Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, at which shareholders elected seven directors, including Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis M. McGrath, Robert Smith, a...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology advances LYMPHIR launch and global expansion
Positive
Apr 1, 2026
On March 31, 2026, Citius Oncology reported early commercial progress for LYMPHIR’s U.S. launch in CTCL, citing strong institutional uptake, repeat orders, and approximately 135 health plans providing coverage representing about 80% of cover...
Business Operations and StrategyProduct-Related Announcements
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
Positive
Mar 10, 2026
On March 10, 2026, Citius Oncology reported positive topline results from an investigator-initiated Phase 1 trial led by the University of Pittsburgh evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gyn...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
Positive
Mar 4, 2026
On March 4, 2026, Citius Oncology reported positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.